Having trouble accessing articles? Reset your cache.

Coda’s chemogenetics convinces investors to re-up in series A extension

Coda raised $15M in a series A extension to begin testing its chemogenetic therapies in animals

Cellular data for Coda’s chemogenetic therapy convinced its existing investors to back a $15 million extension of the company’s series A round, which will enable the biotech to generate in vivo data and choose clinical candidates for neuropathic pain and focal epilepsy.


Read the full 427 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers